ArticleFrontiers in neurology
Maximizing treatment response in patients with neuropathic-subtype postural orthostatic tachycardia syndrome.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Postural Orthostatic Tachycardia Syndrome (POTS) is notoriously difficult to diagnose and successfully treat. POTS encompasses several different subtypes, but little research attention has focused on optimizing the diagnosis and treatment of specific subtypes. This study aims to identify variables potentially predictive of neuropathic POTS and determine which current medical therapies for POTS are most successful in the neuropathic population. Methods: Single-center retrospective review identified 382 patients diagnosed with POTS between 2018 and 2020. Diagnosis was established via the head-up tilt table test; neuropathic subtype was established via skin biopsy or quantitative sudomotor axon reflex test. Logistic regression identified variables predictive of the neuropathic subtype; Cox proportional hazard and Kaplan-Meier estimator modeling were employed to compare treatment response to medications between neuropathic and non-neuropathic patients. Results: Patients with neuropathic POTS treated with ivabradine exhibited a median treatment response duration of 26.7 months in the neuropathic group vs. 10.7 months in the non-neuropathic group, reflecting a significantly reduced risk of treatment failure (hazard ratio = 0.273, Discussion: Patients with neuropathic POTS may exhibit different medication treatment response compared to patients with non-neuropathic POTS, though prospective studies are needed for confirmation. Further study to identify optimal treatment regimens for different subtypes of POTS is a promising direction to improve the quality of care for patients with POTS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.